Glycosaminoglycans During Septic Shock - a Temporal Study - Full Text View

Glycosaminoglycans During Septic Shock - a Temporal Study (GAGS)

This study is currently recruiting participants.

Verified by Region Skane, December 2008

Sponsored by:	Region Skane
Information provided by:	Region Skane
ClinicalTrials.gov Identifier:	NCT00814112

Purpose

We have previously shown that the plasma level of glycosaminoglycans (GAG) in septic shock patients are elevated compared to controls. The purpose of this study is to investigate the temporal dynamic of the blood level of GAG in ten septic shock patients. In addition, to assess the kinetics of GAG during septic shock we examine the liver function by galactose elimination capacity as well as excreted urinary GAG.

Condition
Septic Shock

MedlinePlus related topics: Sepsis

U.S. FDA Resources

Study Type:	Observational
Study Design:	Case Control, Prospective
Official Title:	GAGS - Glykosaminoglykaner Vid Sepsis

Further study details as provided by Region Skane:

Biospecimen Retention: Samples Without DNA

Biospecimen Description:

Plasma and Urine.

Estimated Enrollment:	20
Study Start Date:	November 2008
Estimated Primary Completion Date:	November 2010 (Final data collection date for primary outcome measure)

Groups/Cohorts
1
2

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	Yes
Sampling Method:	Probability Sample

Study Population

Septic Shock

Criteria

Inclusion Criteria:

2 out of 4 SIRS criteria, where the circulatory criteria must be fulfilled
Clinical sepsis is suspected
Informed consent from relative
Study subject must be over 18 years old

Exclusion Criteria:

hematological malignancy
Have received heparin (or analogous) drugs
Autoimmune disease

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00814112

Contacts

Contact: Ingrid Berkestedt, MD	+4646171949	ingrid.berkestedt@skane.se
Contact: Axel Nelson, PhD-student		axel.nelson@med.lu.se

Locations

Sweden
Intensive Care Unit, Lund University Hospital	Recruiting
Lund, Sweden, 22185
Contact: Ingrid Berkestedt, MD +4646171949 ingrid.berkestedt@skane.se
Sub-Investigator: Axel Nelson, PhD student
Sub-Investigator: Ingrid Berkestedt, MD

Sponsors and Collaborators

Region Skane

Investigators

Principal Investigator:

Mikael Bodelsson, professor

Intensive Care Unit, Lund University Hospital, Sweden

More Information

Responsible Party:	Lund University Hospital ( Mikael Bodelsson/Professor )
Study ID Numbers:	GAGS 293/2008
Study First Received:	December 22, 2008
Last Updated:	December 22, 2008
ClinicalTrials.gov Identifier:	NCT00814112
Health Authority:	Sweden: Regional Ethical Review Board

Study placed in the following topic categories:

Systemic Inflammatory Response Syndrome
Sepsis
Shock
Shock, Septic
Inflammation

Additional relevant MeSH terms:

Pathologic Processes
Infection

ClinicalTrials.gov processed this record on January 15, 2009